Kellie Seringer

Partner at Regennabis Ventures at Regennabis
On the record
Represented by:

Kellie Seringer founded Symmetry Capital Management; a health-care focused hedge fund, in October 2001. She now manages public and private funds in the cannabis space and serves as an advisory board member to other companies and funds in the cannabis and ESG space. For nearly, 20 years, Symmetry Capital has focused on small to mid-capitalization biotechnology and medical device companies. Kellie uses a wealth of knowledge in the volatile biotechnology sector for application in research and portfolio management in the Medicus LP public fund and the Regennabis Venture Funds. Her superpower is working closely with management teams to leverage their resources for the greatest corporate impact.

Using this backbone of experience, Kellie implements a substantial skill set to drive change in environment practices and social reform through impact investing. This is the core of her vision, Symmetry Capital is not only focused on outsized returns, but investment for the greater good.

Kellie has 25 years of public, health care equity experience. Prior to founding Symmetry Capital, she had been a co-portfolio manager for the EGM Medical Technology Fund in 2000 and 2001. For the year 2000, the strategy was the 5th overall ranked hedge fund, as reported in January 2001 by Barron’s. Prior to EGM, she held equity research analyst positions at Evolution Capital, Montgomery Securities, now Bank of America Securities, and Dean Witter Reynolds.

Sign up to view all